Gilead Sciences (Nasdaq: GILD) company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy.
After a single infusion of Yescarta, 92% of iNHL patients responded, including 76% of patients achieving a complete response at a median follow-up of 17.5 months.
The data were presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze